By Ben Glickman Shares of Crinetics Pharmaceuticals rose Tuesday after the company reported positive data from an ongoing study of a treatment for carcinoid.
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) traded down 3.8% during trading on Wednesday following insider selling activity. The company traded as low as $32.76 and last traded at $33.04. 482,383 shares were traded during trading, a decline of 37% from the average session volume of 770,039 shares. The stock had previously […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 4,540,000 shares, a growth of 21.4% from the August 15th total of 3,740,000 shares. Based on an average daily volume of 866,100 shares, the short-interest ratio […]
Sanders Morris Harris LLC acquired a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 18,600 shares of the company’s stock, valued at approximately $336,000. A number of other institutional investors and […]
Sanders Morris Harris LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the second quarter, according to its most recent filing with the SEC. The fund acquired 18,600 shares of the company’s stock, valued at approximately $336,000. Other hedge funds have also bought and sold shares of the company. Tower […]